Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 8:07 p.m. and Nov. 22, 2024, 8:07 p.m. in: Finland.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Bailiwick of Jersey
Partnership: Document Extract: TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB) , which is a distributor of medical and surgical products based in New Jersey. TSB is a leading medical solutions provider with 18 sales representatives dedicated to breaking the mold of traditional medical device distribution. Signing of the agreement will enable the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area covering one of the most populated areas of the United States. As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 7:58 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Bailiwick of Jersey
Partnership: Document Extract: TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB) , which is a distributor of medical and surgical products based in New Jersey. TSB is a leading medical solutions provider with 18 sales representatives dedicated to breaking the mold of traditional medical device distribution. Signing of the agreement will enable the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area covering one of the most populated areas of the United States. As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314027.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 7:58 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. " We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs™ Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs™ products in the U.S. and driving demand within the surgeon community", says Alan Donze, CEO of Bioretec Ltd. Further enquiries.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314027.html (archive.org page / archive.org listing)


The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Document Date: Nov. 20, 2024, 1:42 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: United States
Partnership: Document Extract: The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement. Bioretec Ltd Press release 20 November 2024 at 3:30 p.m. EET. TAMPERE, Finland, Nov. 20, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of commercializing its innovative RemeOs™ Trauma Products in the U.S. market. Bioretec strengthens its operational efforts by entering into a new logistics agreement with a partner providing customer support services for U.S. operations. This agreement with GlobalMed Logistix (GMLx) , a leader in healthcare logistics, will enable the smooth import and distribution of implants and instrument sets to hospitals throughout the country, which secures high service levels for customers in the U.S. market.
Document Source: https://www.prnewswire.com/news-releases/the-commercialization-of-bioretecs-remeos-trauma-screw-in-the-us-proceeds-with-the-signing-of-new-logistics-agreement-302311524.html (archive.org page / archive.org listing)


The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Document Date: Nov. 20, 2024, 1:40 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: United States
Partnership: Document Extract: The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement. Bioretec Ltd Press release 20 November 2024 at 3:30 p.m. EET. TAMPERE, Finland, Nov. 20, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of commercializing its innovative RemeOs™ Trauma Products in the U.S. market. Bioretec strengthens its operational efforts by entering into a new logistics agreement with a partner providing customer support services for U.S. operations. This agreement with GlobalMed Logistix (GMLx) , a leader in healthcare logistics, will enable the smooth import and distribution of implants and instrument sets to hospitals throughout the country, which secures high service levels for customers in the U.S. market.
Document Source: https://www.prnewswire.com/news-releases/the-commercialization-of-bioretecs-remeos-trauma-screw-in-the-us-proceeds-with-the-signing-of-new-logistics-agreement-302311521.html (archive.org page / archive.org listing)


Revolutionizing Beauty Retail: JCPenney and Revieve® Drive Exceptional Engagement and Conversions with AI-Powered Beauty Advisors

Document Date: Nov. 19, 2024, 2 p.m. / Source: prweb
Activity Class: PartnershipActivity
Partnership: Document Extract: Revolutionizing Beauty Retail: JCPenney and Revieve® Drive Exceptional Engagement and Conversions with AI-Powered Beauty Advisors. Latest case study reveals JCPenney's outstanding results by leveraging Revieve's innovative Al Advisors and Next Gen True-To-Life Makeup Artist VTO Solutions. HELSINKI and CHICAGO, Nov. 19, 2024 /PRNewswire-PRWeb/ - Revieve®, the leader in personalized digital beauty experiences for beauty brands, retailers, and digital service providers, has announced the outstanding success of its continued partnership with JCPenney. By leveraging Revieve's advanced AI-powered beauty solutions, including cutting-edge AI Skincare and Haircare advisors and next-generation, true-to-life Virtual Try-On for Makeup, JCPenney has experienced substantial growth in customer acquisition, conversion rates, enriched data collection capabilities, and achieved significant gains in customer engagement. This collaboration has not only elevated the customer experience but has also set a new benchmark for innovation and personalization in the retail industry, further solidifying JCPenney's position as a leader in beauty retail.
Document Source: https://www.prweb.com/releases/revolutionizing-beauty-retail-jcpenney-and-revieve-drive-exceptional-engagement-and-conversions-with-ai-powered-beauty-advisors-302309868.html (archive.org page / archive.org listing)


VIAVI Selected by TDC NET to Enable Network Transformation with Advanced, End-to-End Automated Monitoring Across Complex Domains

Document Date: Nov. 19, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Provided_By: Partnership: Awarded: Document Extract: VIAVI Selected by TDC NET to Enable Network Transformation with Advanced, End-to-End Automated Monitoring Across Complex Domains. CHANDLER, Ariz., Nov. 19, 2024 /PRNewswire/ - VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today announced that TDC NET, the largest and most experienced provider of digital infrastructure in Denmark, has selected NITRO® AIOps for end-to-end network monitoring that continuously observes, analyzes, and manages network performance across multiple domains. The deployment of NITRO AIOps is part of TDC NET's larger transformation strategy that includes other vendors integrated by Infosys, a global leader in next-generation digital services and consulting. NITRO AIOps supports TDC NET's transformation objectives by delivering consolidated network monitoring and real automation to drive business productivity. Leveraging advanced AI/ML techniques, this platform from VIAVI enables automated topology mapping, event correlation to identify root cause of network problems and AI-driven forecasting.
Document Source: https://www.prnewswire.com/news-releases/viavi-selected-by-tdc-net-to-enable-network-transformation-with-advanced-end-to-end-automated-monitoring-across-complex-domains-302309644.html (archive.org page / archive.org listing)


Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients

Document Date: Nov. 19, 2024, 1:15 p.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: [ 4 ] Integrating MSIntuit CRC v2 into Concentriq as part of Proscia's precision medicine AI portfolio could have the potential to expand access to the AI diagnostic in pathology labs. Concentriq is an enterprise pathology platform used by major laboratories for all aspects of their daily operations. David West, CEO of Proscia, said: "We are tremendously excited about our partnership with Owkin. Our shared focus on advancing pathology from drug discovery to diagnostics uniquely positions us to unlock the potential of AI on novel therapies and treatment decisions, and our growing base of customers will ensure that breakthroughs are translated into the clinic to benefit patients ." Through the collaboration, Owkin has joined the Proscia Ready partner alliance made up of solution providers helping laboratories and life sciences organizations accelerate the scaled adoption of AI-enabled digital pathology with confidence.
Document Source: https://www.businesswire.com/news/home/20241119179371/en/Owkin-and-Proscia-Expand-Access-to-AI-Pre-Screening-for-Colorectal-Cancer-Patients (archive.org page / archive.org listing)


Troilus Progresses Project Financing with Two Additional LOIs for up to Another US$500 Million from Scandanavian Export Credit Agencies Finnvera (Finland) and EKN (Sweden)

Document Date: Nov. 19, 2024, noon / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Investment
Investor: Target: Document Extract: Troilus has received an LOI from Finnvera, the official export credit agency of Finland, confirming in-principle eligibility for an untied loan guarantee of up to US $ 300 million to support the Project's financing package.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983450/0/en/Troilus-Progresses-Project-Financing-with-Two-Additional-LOIs-for-up-to-Another-US-500-Million-from-Scandanavian-Export-Credit-Agencies-Finnvera-Finland-and-EKN-Sweden.html (archive.org page / archive.org listing)


Paxos to Acquire Finnish E-Money Institution Membrane Finance

Document Date: Nov. 19, 2024, 2 p.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity / Type: Acquisition / Region: Republic of Finland
Buyer: Target: Document Extract: Paxos to Acquire Finnish E-Money Institution Membrane Finance.
Document Source: https://www.prnewswire.com/news-releases/paxos-to-acquire-finnish-e-money-institution-membrane-finance-302310043.html (archive.org page / archive.org listing)


Genpact Announces Renewed Partnership with Ferring Pharmaceuticals

Document Date: Nov. 21, 2024, 1:05 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Renewed multi-year partnership to support Ferring Pharmaceuticals' operations in response to rapid business growth. NEW YORK, Nov. 21, 2024 /PRNewswire/ - Genpact (NYSE: G) , a global professional services and solutions firm delivering outcomes that shape the future, today announced the extension of its partnership with Ferring Pharmaceuticals, a research-driven biopharmaceutical company that has operating subsidiaries in more than 50 countries and markets its medicines in over 100 countries. The renewed multi-year agreement will continue the transformation of Ferring's finance, accounting, and procurement operations with advanced technologies, including AI. " To drive growth in a complex and competitive environment, pharmaceutical companies need modern, scalable and efficient solutions ," said Sanjiv Tandon, Global Head of Life Sciences and Healthcare, Genpact. " Our ongoing partnership with Ferring Pharmaceuticals leverages our industry expertise and a shared vision to harness advanced technologies, setting a new standard for innovation and enabling Ferring to meet evolving demands with speed and accuracy ."
Document Source: https://www.prnewswire.com/news-releases/genpact-announces-renewed-partnership-with-ferring-pharmaceuticals-302312504.html (archive.org page / archive.org listing)


Nokia wins multi-billion 5G extension deal from Bharti Airtel for its India operations

Document Date: Nov. 20, 2024, 7:30 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Nokia wins multi-billion 5G extension deal from Bharti Airtel for its India operations. Press Release. Nokia wins multi-billion 5G extension deal from Bharti Airtel for its India operations. Strengthens its partnership with 4G and 5G contract extension in preparation for 5G-Advanced network evolution. To deploy equipment from its comprehensive AirScale portfolio and its MantaRay solution for intelligent network management.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984153/0/en/Nokia-wins-multi-billion-5G-extension-deal-from-Bharti-Airtel-for-its-India-operations.html (archive.org page / archive.org listing)


Essity expands its athletics tape production in France

Document Date: Nov. 19, 2024, 7:12 a.m. / Source: PR Newswire
Activity Class: LocationActivity / Type: Added
Location_Added_By: Location: Document Extract: Essity expands its athletics tape production in France.
Document Source: https://www.prnewswire.com/news-releases/essity-expands-its-athletics-tape-production-in-france-302309572.html (archive.org page / archive.org listing)


Essity expands its athletics tape production in France

Document Date: Nov. 19, 2024, 7:10 a.m. / Source: PR Newswire
Activity Class: LocationActivity / Type: Added
Location_Added_By: Location: Document Extract: STOCKHOLM, Nov. 19, 2024 /PRNewswire/ - Hygiene and health company Essity is expanding its production of athletics tape by investing in a new production line for Leukotape K. The investment enables a significant increase in production capacity to meet the growing global demand.
Document Source: https://www.prnewswire.com/news-releases/essity-expands-its-athletics-tape-production-in-france-302309566.html (archive.org page / archive.org listing)


Essity expands its athletics tape production in France

Document Date: Nov. 19, 2024, 7:10 a.m. / Source: PR Newswire
Activity Class: LocationActivity / Type: Added
Location_Added_By: Location: Document Extract: Essity expands its athletics tape production in France.
Document Source: https://www.prnewswire.com/news-releases/essity-expands-its-athletics-tape-production-in-france-302309566.html (archive.org page / archive.org listing)


Essity expands its athletics tape production in France

Document Date: Nov. 19, 2024, 7:12 a.m. / Source: PR Newswire
Activity Class: LocationActivity / Type: Added
Location_Added_By: Location: Document Extract: STOCKHOLM, Nov. 19, 2024 /PRNewswire/ - Hygiene and health company Essity is expanding its production of athletics tape by investing in a new production line for Leukotape K. The investment enables a significant increase in production capacity to meet the growing global demand.
Document Source: https://www.prnewswire.com/news-releases/essity-expands-its-athletics-tape-production-in-france-302309572.html (archive.org page / archive.org listing)


Report: T-Mobile may be the next operator to drop Nokia for Ericsson

Document Date: Nov. 19, 2024, 10:23 p.m. / Source: Fierce Network
Activity Class: CorporateFinanceActivity / Type: Acquisition
Vendor: Buyer: Target: Document Extract: Wireless expert and telecom analyst Earl Lum told Fierce this afternoon that he thinks that T-Mobile US will ditch Nokia for its Nordic rival Ericsson because of a multitude of technical issues with its cellular equipment, which he detailed in a LinkedIn piece.
Document Source: https://www.fierce-network.com/wireless/could-ericsson-kick-nokia-out-t-mobile-usa (archive.org page / archive.org listing)


Keto Software Lands €8.4 M Funding to Drive Innovation with its Strategic Portfolio Management Platform

Document Date: Nov. 19, 2024, 4:57 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: Republic of Finland
Investor: Target: Document Extract: Keto Software Lands €8.4 M Funding to Drive Innovation with its Strategic Portfolio Management Platform.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983872/0/en/Keto-Software-Lands-8-4-M-Funding-to-Drive-Innovation-with-its-Strategic-Portfolio-Management-Platform.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. " We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs™ Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs™ products in the U.S. and driving demand within the surgeon community", says Alan Donze, CEO of Bioretec Ltd. Further enquiries.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


Benjamin Capital Taps Joseph Jaffe As First CMO To Accelerate 'Money Moments' Marketplace

Document Date: Nov. 18, 2024, 1 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Oulu, Delray Beach
Role: Person: Organization: Document Extract: DELRAY BEACH, Fla. and OULU, Finland, Nov. 18, 2024 /PRNewswire/ - Benjamin Capital Partners announced today it has hired Joseph Jaffe as its first Chief Marketing Officer.
Document Source: https://www.prnewswire.com/news-releases/benjamin-capital-taps-joseph-jaffe-as-first-cmo-to-accelerate-money-moments-marketplace-302307517.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.